Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa.
Patricia Garbayo SalmonsEva VilarrasaJulio Bassas-VilaVeronica Mora-FernándezIrene FuertesMar Luque-LunaRosa Fornons-ServentGemma Martin-EzquerraRafael Sergio Aguayo-OrtizJoan CeravallsJordi MolletÁlvaro Gómez TomásEmili MasferrerOriol Corral-MagañaClara Matas-NadalJorge Del EstalDiana Fuertes BailónJoan CalvetJorge RomaníPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
ADA demonstrated prolonged survival (median 56.2 months). While addition of antibiotics did not have a positive effect on survival rate, basal IHS4 proved useful in predicting ADA survival.